Our top pick for
Lannett Company Inc is a drug manufacturers-specialty & generic business based in the US. Lannett Company shares (LCI) are listed on the NYSE and all prices are listed in US Dollars. Lannett Company employs 810 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.49|
|52-week range||$2.38 - $10.70|
|50-day moving average||$2.90|
|200-day moving average||$4.18|
|Wall St. target price||$6.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-9.23|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||2.49|
|1 month (2021-09-24)||-19.16%|
|3 months (2021-07-26)||-47.80%|
|6 months (2021-04-26)||-48.66%|
|1 year (2020-10-26)||-63.27%|
|2 years (2019-10-25)||-79.02%|
|3 years (2018-10-26)||3.47|
|5 years (2016-10-26)||21.4|
Valuing Lannett Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lannett Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Lannett Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $31.2 million.
The EBITDA is a measure of a Lannett Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$478.8 million|
|Gross profit TTM||$100.4 million|
|Return on assets TTM||-1.14%|
|Return on equity TTM||-263.94%|
|Market capitalisation||$105.7 million|
TTM: trailing 12 months
There are currently 5.7 million Lannett Company shares held short by investors – that's known as Lannett Company's "short interest". This figure is 0.1% up from 5.7 million last month.
There are a few different ways that this level of interest in shorting Lannett Company shares can be evaluated.
Lannett Company's "short interest ratio" (SIR) is the quantity of Lannett Company shares currently shorted divided by the average quantity of Lannett Company shares traded daily (recently around 689073.34137515). Lannett Company's SIR currently stands at 8.29. In other words for every 100,000 Lannett Company shares traded daily on the market, roughly 8290 shares are currently held short.
However Lannett Company's short interest can also be evaluated against the total number of Lannett Company shares, or, against the total number of tradable Lannett Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lannett Company's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Lannett Company shares in existence, roughly 140 shares are currently held short) or 0.1573% of the tradable shares (for every 100,000 tradable Lannett Company shares, roughly 157 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Lannett Company.
Find out more about how you can short Lannett Company stock.
We're not expecting Lannett Company to pay a dividend over the next 12 months.
Lannett Company's shares were split on a 3:2 basis on 2 March 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Lannett Company shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Lannett Company shares which in turn could have impacted Lannett Company's share price.
Over the last 12 months, Lannett Company's shares have ranged in value from as little as $2.38 up to $10.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Lannett Company's is 1.0624. This would suggest that Lannett Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.